Athersys, Inc.  

(Public, NASDAQ:ATHX)   Watch this stock  
Find more results for Harrington Campbell
1.15
+0.01 (0.88%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.13 - 1.17
52 week 0.90 - 3.43
Open 1.14
Vol / Avg. 236,424.00/360,254.00
Mkt cap 95.58M
P/E     -
Div/yield     -
EPS -0.31
Shares 83.12M
Beta 0.48
Inst. own 22%
Nov 9, 2015
Q3 2015 Athersys Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 6, 2015
Q2 2015 Athersys Inc Earnings Call - Webcast
Aug 6, 2015
Q2 2015 Athersys Inc Earnings Release
Jun 24, 2015
Athersys Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -479.17% -1360.57%
Operating margin -3256.48% -1787.55%
EBITD margin - -1765.37%
Return on average assets -10.83% -70.21%
Return on average equity -20.56% -108.47%
Employees 57 -
CDP Score - -

Address

3201 Carnegie Ave
CLEVELAND, OH 44115-2634
United States - Map
+1-216-4319900 (Phone)
+1-216-3619495 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Athersys Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy is being evaluated in multiple clinical trials. Its current clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease and other conditions. It is also identifying and developing small molecule compounds with applications in indications, such as obesity, related metabolic conditions and neurological conditions. It is engaged in the preparation stages for clinical studies in other targeted areas, including the treatment of ARDS. Its current programs include Ischemic Stroke, Acute Myocardial Infarction, Acute Respiratory Distress Syndrome, Hematopoietic Stem Cell Transplant/GvHD and Inflammatory Bowel Disease. In addition to the programs, it is also conducting or supporting clinical activity in other areas, such as solid organ transplant.

Officers and directors

Gil Van Bokkelen Ph.D. Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
William Lehmann Jr., J.D. President, Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
John J. Harrington Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 47
Bio & Compensation  - Reuters
Robert J. Deans Ph.D. Executive Vice President - Regenerative Medicine
Age: 63
Bio & Compensation  - Reuters
Laura K. Campbell CPA Vice President - Finance
Age: 51
Bio & Compensation  - Reuters
Lee E. Babiss Ph.D. Lead Independent Director
Age: 59
Bio & Compensation  - Reuters
Ismail Kola Independent Director
Age: 58
Bio & Compensation  - Reuters
Lorin Jeffry Randall Independent Director
Age: 71
Bio & Compensation  - Reuters
Kenneth H. Traub Independent Director
Age: 53
Bio & Compensation  - Reuters
Jack L. Wyszomierski Independent Director
Age: 59
Bio & Compensation  - Reuters